Quadrivalent vaccine type HPV prevalence in young U.S. women has declined steeply even though vaccine coverage remains incomplete.
Despite the recommendation to vaccinate girls and women aged 11 through 27 against human papillomavirus (HPV), uptake in the U.S. has been slow. Investigators used CDC survey data to assess HPV prevalence in U.S. women aged 14 to 34 before (2003–2006) versus after (2009–2012) the introduction of HPV vaccination.
Prevalence of the HPV types included in the quadrivalent vaccine (4vHPV; 6, 11, 16, and 18) fell 64% in 14- to 19-year-old women (from 11.5% to 4.6%) and 34% in 20- to 24-year-old women (from 18.5% to 12.1%). Almost all of this decrease occurred among women who reported receiving at least one dose of 4vHPV. Among vaccinated women, 4vHPV type prevalence declined 91% (compared with 13% in unvaccinated women). This relative lack of decl…
Reviewing Author
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)